Design Module
The Design Module contains detailed information about the study design, including study type, allocation methods, intervention models, masking information, primary purpose, enrollment details, and biospecimen information. This module provides essential details about how the clinical trial is structured and conducted.
Design Module path is as follows:
Study -> Protocol Section -> Design Module
Design Module
Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2025-12-25 @ 2:15 AM
NCT ID:
NCT00801060
Study Type:
INTERVENTIONAL
Allocation:
RANDOMIZED
Primary Purpose:
TREATMENT
Study:
NCT00801060
Study Brief:
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Protocol Section:
NCT00801060
Bio Specs (If Any):
Design Masking Infos (If Any):
Design Masking Infos
| Design Masking Brief | View |
|---|---|
| None | View |
Design Observational Models (If Any):
Design Time Perspectives (If Any):
Design Who Masked (If Any):
Enrollment Infos (If Any):
Enrollment Infos
| Enrollment Type | Enrollment Count | View |
|---|---|---|
| ACTUAL | 40 | View |
Expanded Access Types (If Any):
Phases (If Any):
Phases
| Phase Brief | Phase Text | View |
|---|---|---|
| None | PHASE2 | View |